Showing 1 – 20 of 352
Relevance | Newest | Oldest |
  • JAMA February 23, 2016

    Figure: Platelet Counts by Circulating Histone Level Among Patients With Thrombocytopenia Who Are Critically Ill

    P values are calculated by Mann-Whitney U test. Horizontal bars represent median levels. The percentage of decrease in platelet counts is calculated in reference to platelet count on admission. Thrombocytopenic patients with high admission histones (≥30 ug/mL) have significantly lower platelet counts and higher percentage of decrease in platelet counts at 24 hours (P = .02 and P = .04, respectively) and 48 hours (P = .003 and P = .005, respectively) after intensive care unit admission.
  • JAMA February 23, 2016

    Figure 4: Serum Lactate Level Analysis

    Adjusted odds ratio for actual serum lactate levels for the entire septic shock cohort (N = 18 840). The covariates used in the regression model include region (United States and Europe), location where sepsis was suspected (emergency department, ward, or critical care unit), antibiotic administration, steroid use, organ failures (pulmonary, renal, hepatic, and acutely altered mental state), infection source (pneumonia, urinary tract infection, abdominal, meningitis, and other), hyperthermia (>38.3°C), hypothermia (<36°C), chills with rigor, tachypnea (>20/min), leukopenia (<4000 cells/µL), hyperglycemia (plasma glucose >120 mg/dL [6.7 mmol/L]), platelet count <100 ×103/μL, and coagulopathy (eMethods 3 in the Supplement). The adjusted odds ratio (OR) for the 6 groups presented in eTable 7 in the Supplement and the adjusted OR for the individual variables (lactate, vasopressor therapy, and fluids) are reported in eTable 8 in the Supplement. To convert serum lactate values to mg/dL, divide by 0.111.
  • JAMA April 21, 2015

    Figure 4: Platelet Reconstitution After Gene Therapy

    A, Change over time in platelet count in each patient. The lower normal value is indicated by a dotted line. Solid lines connecting the triangles indicate continuous platelet transfusions; dashed lines, continuous administration of romiplostim. B, Wiskott-Aldrich syndrome protein (WASp) expression in platelets, as measured by flow cytometry.
  • JAMA April 21, 2015

    Figure 5: Correlation Between Platelet Reconstitution and Number of Transduced Cells Infused

    The platelet count at last follow-up (Table 3) was plotted against the number of transduced CD34+ cells infused per kilogram of body weight, which was calculated by taking account of vector copy number values below 1.0 in the infused product (Table 2).
  • JAMA February 17, 2015

    Figure 3: Changes in the Secondary End Points of Hemoglobin Level, Liver Volume, and Platelet Count in the Intention-to-Treat Population

    For absolute mean changes in hemoglobin level, liver volume, and platelet count, error bars indicate 95% CIs. For individual baseline and 9-month values for each patient, patients are ordered in each graph from the lowest to the highest baseline value. Mean baseline values were as follows: for hemoglobin level, eliglustat, 12.1 g/dL, and placebo, 12.8 g/dL; for liver volume, eliglustat, 1.4 multiples of normal, and placebo, 1.4 multiples of normal; for platelet count, eliglustat, 75 × 109/L, and placebo, 79 × 109/L.aIndicates the single patient who withdrew from the trial; this patient in the eliglustat group withdrew for personal reasons at 3 months and had no 6-month or 9-month assessments. For the final efficacy assessments, change for this patient was determined by last observation carried forward; thus, for liver volume, the baseline value was carried forward, and for hemoglobin level and platelet count, the 3-month value was carried forward.
  • Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1: The ENGAGE Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2015; 313(7):695-706. doi: 10.1001/jama.2015.459

    This international randomized clinical trial found that among adults with Gaucher disease type 1, treatment with eliglustat for 9 months resulted in significant improvements in spleen volume, hemoglobin level, liver volume, and platelet count compared with placebo.

  • JAMA October 19, 2011

    Figure 1: Platelet Count Data for Index Case Patient According to Exposure to Different Dialyzer Membranes

    E-beam indicates electron beam. Patient received a successful transplant on October 23, 2009.
  • Use of Electron-Beam Sterilized Hemodialysis Membranes and Risk of Thrombocytopenia

    Abstract Full Text
    free access
    JAMA. 2011; 306(15):1679-1687. doi: 10.1001/jama.2011.1499
  • JAMA October 19, 2011

    Figure 3: Significant Thrombocytopenia in Patients With Hemodialysis Before and After Change From E-Beam to Non–E-Beam Sterilized Dialyzers in British Columbia and Alberta

    E-beam indicates electron beam. Error bars indicate 95% CIs. Number of patients included in predialysis and postdialysis platelet counts in British Columbia for e-beam sterilized dialyzers (before intervention), n = 1706; and for non–e-beam sterilized dialyzers (postintervention), n = 1784. Number of patients included in predialysis and postdialysis platelet counts in Alberta for e-beam sterilized dialyzers (before intervention), n = 425; and for non–e-beam sterilized dialyzers (postintervention), n = 439.
  • JAMA February 23, 2011

    Figure 2: Hematologic Responses to Alemtuzumab in a Patient With Myelodysplastic Syndromes (MDS)

    Transfusion independence for red blood cells is defined according to the International Working Group Criteria for MDS as a stable hemoglobin level of at least 9 g/dL without transfusions for at least 8 weeks, and for platelet count as a stable platelet count greater than 10 000/μL for at least 8 weeks without transfusions.
  • JAMA September 10, 2003

    Figure 2: Kaplan-Meier Curve of the Percentage of Patients by Treatment Group Who Had Thrombocytopenia at Each Day After Study Entry

    All patients had thrombocytopenia (platelet count <140 ×103/µL) at entry, and the event for the curve is return to normal count.
  • Risk Factors for Traumatic and Bloody Lumbar Puncture in Children With Acute Lymphoblastic Leukemia

    Abstract Full Text
    free access
    JAMA. 2002; 288(16):2001-2007. doi: 10.1001/jama.288.16.2001
  • Safety of Lumbar Puncture for Children With Acute Lymphoblastic Leukemia and Thrombocytopenia

    Abstract Full Text
    free access
    JAMA. 2000; 284(17):2222-2224. doi: 10.1001/jama.284.17.2222
  • Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization: The TRILOGY ACS Platelet Function Substudy

    Abstract Full Text
    free access
    JAMA. 2012; 308(17):1785-1794. doi: 10.1001/jama.2012.17312
    Gurbel and coauthors compare the effect of clopidogrel with prasugrel on platelet reactivity among 2564 patients—who were part of a substudy of the TRILOGY ASC trial—whose acute coronary syndromes, which did not include ST-segment elevation, were managed medically. In an editorial, Price discusses implications of the study for clinical practice and future research.
  • Fatigue and an Elevated White Blood Cell Count

    Abstract Full Text
    JAMA. 2015; 314(6):617-618. doi: 10.1001/jama.2015.4882

    A 67-year-old woman presented with fatigue for 4 weeks; a history of type 2 diabetes mellitus, hypertension, hyperlipidemia, and allergic rhinitis; and leukocytosis with predominant granulocytes. What’s the diagnosis?

  • Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma: The PROPPR Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2015; 313(5):471-482. doi: 10.1001/jama.2015.12

    This randomized trial reports that among patients with severe trauma and major bleeding, early administration of plasma, platelets, and red blood cells in a 1:1:1 ratio compared with a 1:1:2 ratio did not result in significant differences in mortality at 24 hours or at 30 days.

  • Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation

    Abstract Full Text
    free access
    JAMA. 2010; 303(8):754-762. doi: 10.1001/jama.2010.181
  • Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease

    Abstract Full Text
    free access
    JAMA. 2011; 306(20):2221-2228. doi: 10.1001/jama.2011.1703
  • Sex Differences in Platelet Reactivity and Response to Low-Dose Aspirin Therapy

    Abstract Full Text
    free access
    JAMA. 2006; 295(12):1420-1427. doi: 10.1001/jama.295.12.1420